Aa
omg!
Omg! I am absolutely mortified! The rash is coming back after a round of steroids. That was the most torturous side effect for me. Feeling pretty defeated. Any suggestions would be appreciated. A possible name of the rash? Wanna try to look it up..thanx.
Thanx for your response I'm just highly reactive still. Been done with treatment for over a month. And it subsided on the steroids.....
Did you ever have chicken pox? Have you ever been tested for shingles. About every two or three years I will do a bout with it, always in the spring, always on my forehead and sides of my face and my arms.... It is painful. don't scratch. Press. See your doctor and get some blood tests.
I sorry your still having problems and hope you get rid of this rash . When you get a chance please update us. Latest doctors diagnosis, recommendation and treatment and/or you need some emotional support And when hopefully the problem is resolved.
Thanx for your responsive I'm just highly reactive still. Been done with treatment for over a month. And it subsided on the steroids.....
Thank you so much for this info. I am so scared this wont go away....a post interferon situation.....thanx again
"A possible name of the rash? Wanna try to look it up..thanx."
Incivek
WARNING: SERIOUS SKIN REACTIONS
Fatal and non-fatal serious skin reactions, including Stevens Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with Incivek combination treatment. Fatal cases have been reported in patients with progressive rash and systemic symptoms who continued to receive Incivek combination treatment after a serious skin reaction was identified [see Warnings and Precautions (5.1)].
For serious skin reactions, including rash with systemic symptoms or a progressive severe rash, Incivek, peginterferon alfa, and ribavirin must be discontinued immediately. Discontinuing other medications known to be associated with serious skin reactions should be considered. Patients should be promptly referred for urgent medical care [see Warnings and Precautions (5.1)].
Post-marketing Experience
The following adverse reactions have been identified during post-approval use of Incivek. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and Subcutaneous Tissue Disorders: Toxic Epidermal Necrolysis (TEN) and Erythema Multiforme (EM) [see also Boxed Warning and Warnings and Precautions (5.1)]
Warnings and Precautions
Serious Skin Reactions/Rash
Fatal and non-fatal serious skin reactions, including Stevens Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with Incivek combination treatment. Fatal cases have been reported in patients with progressive rash and systemic symptoms who continued to receive Incivek combination treatment after a serious skin reaction was identified.
For serious skin reactions, including rash with systemic symptoms or a progressive severe rash, Incivek, peginterferon alfa, and ribavirin must be discontinued immediately. Discontinuing other medications known to be associated with serious skin reactions should be considered. Patients should be promptly referred for urgent medical care.
In clinical trials, serious skin reactions, including DRESS and SJS were reported in less than 1% of subjects who received Incivek combination treatment compared to none who received peginterferon alfa and ribavirin alone. These serious skin reactions required hospitalization, and all subjects recovered. The presenting signs of DRESS may include rash, fever, facial edema, and evidence of internal organ involvement (e.g., hepatitis, nephritis). Eosinophilia may or may not be present. The presenting signs of SJS may include fever, target lesions, and mucosal erosions or ulcerations (e.g., conjunctivae, lips).
TEN and Erythema Multiforme (EM) have been observed in post-marketing experience [see also Boxed Warning and Adverse Reactions (6.2)].
Rash events (all grades) developed in 56% of subjects who received Incivek combination treatment [see Adverse Reactions (6.1)] and in 34% of subjects who received peginterferon alfa and ribavirin. Rash most frequently began during the first 4 weeks, but could occur at any time during Incivek combination treatment. Rash events led to discontinuation of Incivek alone in 6% of subjects and discontinuation of Incivek combination treatment in 1% of subjects. Severe rash (e.g., a generalized rash or rash with vesicles or bullae or ulcerations other than SJS) was reported in 4% of subjects who received Incivek combination treatment compared to less than 1% who received peginterferon alfa and ribavirin alone. The severe rash may have a prominent eczematous component.
Patients with mild to moderate rashes should be followed for progression of rash or development of systemic symptoms. If rash progresses and becomes severe, Incivek should be discontinued. Peginterferon alfa and ribavirin may be continued. If improvement is not observed within 7 days of Incivek discontinuation, sequential or simultaneous interruption or discontinuation of ribavirin and/or peginterferon alfa should be considered. If medically indicated, earlier interruption or discontinuation of ribavirin and peginterferon alfa should be considered [see also Boxed Warning]. Patients should be monitored until the rash has resolved. Incivek must not be reduced or restarted if discontinued due to rash. Treatment of rash with oral antihistamines and/or topical corticosteroids may provide symptomatic relief but effectiveness of these measures has not been established. Treatment of rash with systemic corticosteroids is not recommended [see Drug Interactions (7)].
http://www.drugs.com/pro/incivek.html
Incivek
WARNING: SERIOUS SKIN REACTIONS
Fatal and non-fatal serious skin reactions, including Stevens Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with Incivek combination treatment. Fatal cases have been reported in patients with progressive rash and systemic symptoms who continued to receive Incivek combination treatment after a serious skin reaction was identified [see Warnings and Precautions (5.1)].
For serious skin reactions, including rash with systemic symptoms or a progressive severe rash, Incivek, peginterferon alfa, and ribavirin must be discontinued immediately. Discontinuing other medications known to be associated with serious skin reactions should be considered. Patients should be promptly referred for urgent medical care [see Warnings and Precautions (5.1)].
Post-marketing Experience
The following adverse reactions have been identified during post-approval use of Incivek. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and Subcutaneous Tissue Disorders: Toxic Epidermal Necrolysis (TEN) and Erythema Multiforme (EM) [see also Boxed Warning and Warnings and Precautions (5.1)]
Warnings and Precautions
Serious Skin Reactions/Rash
Fatal and non-fatal serious skin reactions, including Stevens Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN), have been reported in patients treated with Incivek combination treatment. Fatal cases have been reported in patients with progressive rash and systemic symptoms who continued to receive Incivek combination treatment after a serious skin reaction was identified.
For serious skin reactions, including rash with systemic symptoms or a progressive severe rash, Incivek, peginterferon alfa, and ribavirin must be discontinued immediately. Discontinuing other medications known to be associated with serious skin reactions should be considered. Patients should be promptly referred for urgent medical care.
In clinical trials, serious skin reactions, including DRESS and SJS were reported in less than 1% of subjects who received Incivek combination treatment compared to none who received peginterferon alfa and ribavirin alone. These serious skin reactions required hospitalization, and all subjects recovered. The presenting signs of DRESS may include rash, fever, facial edema, and evidence of internal organ involvement (e.g., hepatitis, nephritis). Eosinophilia may or may not be present. The presenting signs of SJS may include fever, target lesions, and mucosal erosions or ulcerations (e.g., conjunctivae, lips).
TEN and Erythema Multiforme (EM) have been observed in post-marketing experience [see also Boxed Warning and Adverse Reactions (6.2)].
Rash events (all grades) developed in 56% of subjects who received Incivek combination treatment [see Adverse Reactions (6.1)] and in 34% of subjects who received peginterferon alfa and ribavirin. Rash most frequently began during the first 4 weeks, but could occur at any time during Incivek combination treatment. Rash events led to discontinuation of Incivek alone in 6% of subjects and discontinuation of Incivek combination treatment in 1% of subjects. Severe rash (e.g., a generalized rash or rash with vesicles or bullae or ulcerations other than SJS) was reported in 4% of subjects who received Incivek combination treatment compared to less than 1% who received peginterferon alfa and ribavirin alone. The severe rash may have a prominent eczematous component.
Patients with mild to moderate rashes should be followed for progression of rash or development of systemic symptoms. If rash progresses and becomes severe, Incivek should be discontinued. Peginterferon alfa and ribavirin may be continued. If improvement is not observed within 7 days of Incivek discontinuation, sequential or simultaneous interruption or discontinuation of ribavirin and/or peginterferon alfa should be considered. If medically indicated, earlier interruption or discontinuation of ribavirin and peginterferon alfa should be considered [see also Boxed Warning]. Patients should be monitored until the rash has resolved. Incivek must not be reduced or restarted if discontinued due to rash. Treatment of rash with oral antihistamines and/or topical corticosteroids may provide symptomatic relief but effectiveness of these measures has not been established. Treatment of rash with systemic corticosteroids is not recommended [see Drug Interactions (7)].
http://www.drugs.com/pro/incivek.html
" can see my doc due to a front office staffs incompetency. its my eye highly bothersome and worrysome" from your post a couple weeks ago
Have no "rash" knowledge. In my non medical opinion If it's that serious of a concern I would insist on seeing a doctor and/or another one asap the next day or if more serious go to the ER.
Best of luck.
Have no "rash" knowledge. In my non medical opinion If it's that serious of a concern I would insist on seeing a doctor and/or another one asap the next day or if more serious go to the ER.
Best of luck.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
From what I remember it takes up to 3 months for the inf to leave the body and up to 6 months for the riba.
I have heard of others having a rash after finishing tx. Hang in there
Dee